Novartis: to present new data on psoriasis drug Cosentyx
(CercleFinance.com) - Novartis will present 26 abstracts on Cosentyx in ankylosing spondylitis and psoriatic arthritis at the upcoming annual European congress of rheumatology, the Swiss drugmaker said on Wednesday.
Data will cover updates on radiographic progression, quality of life and real-world evidence of patient satisfaction with Cosentyx, the company said.
To date, the psoriasis drug has been prescribed to over 150,000 patients to worldwide, according to Novartis.
EULAR 2018 will be held from 13 to 16 June in Amsterdam.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Data will cover updates on radiographic progression, quality of life and real-world evidence of patient satisfaction with Cosentyx, the company said.
To date, the psoriasis drug has been prescribed to over 150,000 patients to worldwide, according to Novartis.
EULAR 2018 will be held from 13 to 16 June in Amsterdam.
Copyright (c) 2018 CercleFinance.com. All rights reserved.